DefinitionThis section has been translated automatically.
Non-glycosylated granulocyte colony stimulating factor produced by recombinant DNA technology.
IndicationThis section has been translated automatically.
Reduction of the duration of neutropenia and reduction of neutropenic fever in patients treated with myelosuppressive chemotherapy (e.g. doxorubicin) due to a non-myeloidal underlying disease. Long-term therapy of severe congenital or idiopathic neutropenia. No influence on chemotherapy-induced thrombopenia and anaemia.
Notice!
Caution with malignant and premalignant diseases of myeloid origin. Use only under the supervision of oncologically experienced doctors!You might also be interested in
Dosage and method of useThis section has been translated automatically.
5-10 μg/kg bw/day i.v. or s.c. Start at the earliest 24 hours after chemotherapy until the neutrophil granulocytes are back to normal. In long-term therapy, injection if the neutrophils drop below the normal value (usually 1-2 times/week).
Undesirable effectsThis section has been translated automatically.
ARDS, BB changes, splenomegaly, liver damage, gastrointestinal disorders, dysuria, proteinuria, allergic reactions, RR drop, fever, chills, paresthesia, myalgias.
Notice! Transition of myelodysplastic syndromes to acute myeloid leukemias!
ContraindicationThis section has been translated automatically.
Pregnancy, lactation, basic myeloid disease, restricted bone marrow function of unclear etiology, liver and kidney failure.
PreparationsThis section has been translated automatically.
Neupogen
Note(s)This section has been translated automatically.
Induction of a sweet syndrome after taking Filgrastim has been described.
LiteratureThis section has been translated automatically.
- Callen JP et al (2002) Neutrophilic dermatoses. Dermatol Clin 20: 409-441
Prof. Dr. med. Peter Altmeyer